38,396 Shares in Spark Therapeutics Inc (ONCE) Purchased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC acquired a new stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 38,396 shares of the biotechnology company’s stock, valued at approximately $1,974,000. Mutual of America Capital Management LLC owned approximately 0.10% of Spark Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sumitomo Mitsui Asset Management Company LTD acquired a new stake in Spark Therapeutics in the fourth quarter valued at approximately $1,098,000. SG Americas Securities LLC lifted its stake in Spark Therapeutics by 90.5% in the fourth quarter. SG Americas Securities LLC now owns 32,606 shares of the biotechnology company’s stock valued at $1,677,000 after acquiring an additional 15,493 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Spark Therapeutics by 11.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 144,632 shares of the biotechnology company’s stock valued at $7,437,000 after acquiring an additional 15,062 shares during the last quarter. Ipswich Investment Management Co. Inc. acquired a new stake in Spark Therapeutics in the fourth quarter valued at approximately $480,000. Finally, Belpointe Asset Management LLC acquired a new stake in Spark Therapeutics in the third quarter valued at approximately $403,000. 95.87% of the stock is currently owned by hedge funds and other institutional investors.

ONCE has been the subject of a number of analyst reports. Royal Bank of Canada restated a “buy” rating on shares of Spark Therapeutics in a research note on Wednesday, October 25th. UBS Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $92.00 to $51.00 in a research note on Tuesday, December 12th. Leerink Swann cut shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 price objective for the company. in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $105.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Chardan Capital reduced their price objective on shares of Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics presently has a consensus rating of “Buy” and an average target price of $73.73.

In related news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $71.32, for a total transaction of $356,600.00. Following the transaction, the insider now owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,018 shares of company stock valued at $1,058,834. Corporate insiders own 7.30% of the company’s stock.

Spark Therapeutics Inc (ONCE) opened at $54.80 on Wednesday. The company has a market cap of $2,030.00, a price-to-earnings ratio of -7.61 and a beta of 3.02. Spark Therapeutics Inc has a one year low of $41.06 and a one year high of $91.75.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/38396-shares-in-spark-therapeutics-inc-once-purchased-by-mutual-of-america-capital-management-llc.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply